ArticleBMC cancer2026
Application of cervical combined with bilateral uterine cornual injection of tracer in sentinel lymph node mapping of early endometrial cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveCurrently, sentinel lymph node (SLN) mapping in early-stage endometrial cancer typically involves a single-site cervical injection. While this method reliably identifies SLNs along the cervical drainage pathway, it has limited sensitivity for detecting SLNs that follow the uterine body pathway, particularly paraaortic lymph nodes. In this study, the combined injection of tracer into the cervix and bilateral uterine cornua allows for the identification of sentinel lymph nodes in both the uterine body and cervical drainage pathways.
methodsForty patients with early-stage endometrial cancer participated in a study for SLN mapping of the cervix and uterine body. Initially, 1 mL CNPs was injected into each uterine cornu at a depth of 0.3-1.0 cm to identify and remove paraaortic SLNs. Next, 1 mL CNPs was injected at the 3 and 9 o'clock positions on the cervix to locate pelvic SLNs. Concurrently, we retrospectively collected data on 40 patients treated at our hospital from June 2023 to June 2024 who received a single-site CNP injection in the cervix, serving as a control group. This study has been registered at the Chinese Clinical Trial Registry (Registration Number: ChiCTR2600120340, Registration Date: March 12,2026).
resultsThe cervical combined with bilateral uterine cornua SLN localization strategy demonstrates a remarkably high detection rate, with an overall sentinel lymph node detection rate of 97.5% (39/40) and a bilateral pelvic SLN visualization rate of 80% (32/40). The paraaortic SLN detection rate was 87.5% (35/40), while isolated paraaortic SLN detection was 5% (2/40). In the control group, the pelvic SLN detection rate was 95% (38/40), and the bilateral pelvic SLN visualization rate was 90% (36/40). The paraaortic SLN detection rate in the control group was 5% (2/40). Notably, the experimental group showed a significant increase in the successful detection rate of paraaortic sentinel lymph nodes, rising from 5% (2/40) in the control group to 87.5% (35/40), with this difference being statistically significant (P < 0.001).
conclusionThe SLN positioning strategy, which combines the cervix with bilateral uterine cornuas, effectively identifies lymph nodes of the fundus and cervical drainage. This strategy offers a higher visualization rate of paraaortic lymph nodes and can detect isolated paraaortic lymph node metastases compared to the cervical injection method. It is also feasible for evaluating sentinel lymph nodes in endometrial cancer.
trial registrationThis study has been registered at the Chinese Clinical Trial Registry (Registration Number: ChiCTR2600120340, Registration Date: March 12,2026).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.